Thermo Fisher Scientific Inc. $TMO Shares Purchased by iA Global Asset Management Inc.

iA Global Asset Management Inc. boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 234,697 shares of the medical research company’s stock after purchasing an additional 5,246 shares during the period. Thermo Fisher Scientific comprises 1.6% of iA Global Asset Management Inc.’s holdings, making the stock its 10th largest position. iA Global Asset Management Inc.’s holdings in Thermo Fisher Scientific were worth $115,361,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Assetmark Inc. grew its holdings in shares of Thermo Fisher Scientific by 22.9% in the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after acquiring an additional 7,023 shares in the last quarter. Mackenzie Financial Corp raised its holdings in Thermo Fisher Scientific by 29.4% during the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock worth $134,130,000 after acquiring an additional 62,790 shares in the last quarter. North Dakota State Investment Board acquired a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $7,505,000. Quadrant Capital Group LLC grew its stake in Thermo Fisher Scientific by 30.9% in the third quarter. Quadrant Capital Group LLC now owns 14,277 shares of the medical research company’s stock valued at $6,924,000 after purchasing an additional 3,369 shares in the last quarter. Finally, EdgePoint Investment Group Inc. increased its position in shares of Thermo Fisher Scientific by 5.0% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 1,388,662 shares of the medical research company’s stock worth $673,529,000 after purchasing an additional 65,597 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 1.2%

Shares of Thermo Fisher Scientific stock opened at $500.36 on Wednesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The business has a fifty day simple moving average of $473.35 and a two-hundred day simple moving average of $518.92. Thermo Fisher Scientific Inc. has a 1 year low of $403.36 and a 1 year high of $643.99. The company has a market capitalization of $185.94 billion, a price-to-earnings ratio of 27.51, a P/E/G ratio of 2.24 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the company earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

Analysts Set New Price Targets

TMO has been the subject of several recent analyst reports. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Finally, Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $605.09.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.